SkylineDx is an emerging commercial-stage company focused on the development and commercialization of innovative gene signature-based diagnostic tests, which assist healthcare professionals in making personalized treatment decisions for individual patients. These tests are designed to accurately determine the type or status of the disease or to predict a patient’s response to a specific treatment. Based on the test results, healthcare professionals can tailor the treatment to the individual patient.
Our lead product is the MMprofiler™, an innovative test that identifies Multiple Myeloma (MM, bone marrow cancer) patients with a poor prognosis and favorable prognosis. This test measures the activity of 92 genes that are directly and indirectly related to the disease. The MMprofiler™ is run on our proprietary Profiler™ platform, a fully secured, centralized data analysis system for complex genetic diagnostic tests.
- Development and commercialization of new diagnostic tools using genomics technology
- Discovery of genetic biomarkers or signatures of clinical relevance
- Specialties: Multiple Myeloma, Gene Expression Profiling, and Improve health outcomes by increasing the effectiveness of treatment for the individual patient.